Alpha 2.0
Login Register
» Articles » PMID: 38577439

Combining Prognostic Value of Serum Carbohydrate Antigen 19-9 and Tumor Size Reduction Ratio in Pancreatic Ductal Adenocarcinoma

Overview
Journal World J Gastrointest Oncol
Publisher Baishideng Publishing Group
Date 2024 Apr 5
PMID 38577439
Authors
Dong-Qin Xia
Yong Zhou
Shuang Yang
Fang-Fei Li
Li-Ya Tian
Yan-Hua Li
Hai-Yan Xu
Cai-Zhi Xiao
Wei Wang
Affiliations
Soon will be listed here.
Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) is a common cancer with increasing morbidity and mortality due to changes of social environment.

Aim: To evaluate the significance of serum carbohydrate antigen 19-9 (CA19-9) and tumor size changes pre- and post-neoadjuvant therapy (NAT).

Methods: This retrospective study was conducted at the Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital. This study specifically assessed CA19-9 levels and tumor size before and after NAT.

Results: A total of 156 patients who completed NAT and subsequently underwent tumor resection were included in this study. The average age was 65.4 ± 10.6 years and 72 (46.2%) patients were female. Before survival analysis, we defined the post-NAT serum CA19-9 level/pre-NAT serum CA19-9 level as the CA19-9 ratio (CR). The patients were divided into three groups: CR < 0.5, CR > 0.5 and < 1 and CR > 1. With regard to tumor size measured by both computed tomography and magnetic resonance imaging, we defined the post-NAT tumor size/pre-NAT tumor size as the tumor size ratio (TR). The patients were then divided into three groups: TR < 0.5, TR > 0.5 and < 1 and TR > 1. Based on these groups divided according to CR and TR, we performed both overall survival (OS) and disease-free survival (DFS) analyses. Log-rank tests showed that both OS and DFS were significantly different among the groups according to CR and TR ( < 0.05). CR and TR after NAT were associated with increased odds of achieving a complete or near-complete pathologic response. Moreover, CR (hazard ratio: 1.721, 95%CI: 1.373-3.762; = 0.006), and TR (hazard ratio: 1.435, 95%CI: 1.275-4.363; = 0.014) were identified as independent factors associated with OS.

Conclusion: This study demonstrated that post-NAT serum CA19-9 level/pre-NAT serum CA19-9 level and post-NAT tumor size/pre-NAT tumor size were independent factors associated with OS in patients with PDAC who received NAT and subsequent surgical resection.

References
1.
Grossberg A, Chu L, Deig C, Fishman E, Hwang W, Maitra A . Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin. 2020; 70(5):375-403. PMC: 7722002. DOI: 10.3322/caac.21626. View
2.
Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar J, Besselink M, Bonsing B . Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020; 38(16):1763-1773. PMC: 8265386. DOI: 10.1200/JCO.19.02274. View
3.
Yao J, Cao K, Hou Y, Zhou J, Xia Y, Nogues I . Deep Learning for Fully Automated Prediction of Overall Survival in Patients Undergoing Resection for Pancreatic Cancer: A Retrospective Multicenter Study. Ann Surg. 2022; 278(1):e68-e79. DOI: 10.1097/SLA.0000000000005465. View
4.
Scara S, Bottoni P, Scatena R . CA 19-9: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015; 867:247-60. DOI: 10.1007/978-94-017-7215-0_15. View
5.
Aoki S, Motoi F, Murakami Y, Sho M, Satoi S, Honda G . Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients. BMC Cancer. 2019; 19(1):252. PMC: 6427838. DOI: 10.1186/s12885-019-5460-4. View